GeoVax Labs, Inc. (Nasdaq: GOVX) has outlined near-term development milestones and strategic priorities for its oncology program Gedeptin, as the company prepares to initiate a Phase 2 clinical trial and pursue partnership opportunities. The announcement comes as combination regimens become increasingly central to oncology treatment, and GeoVax believes its gene-directed enzyme prodrug therapy (GDEPT) is well positioned for integration into established therapeutic backbones.
GeoVax is advancing Gedeptin with a focus on combination with immune checkpoint inhibitors (ICIs) and other standard therapies. The company is preparing to launch a Phase 2 trial evaluating Gedeptin in combination with an ICI as a first-line neoadjuvant treatment for patients with resectable locally advanced head and neck cancer, with trial initiation targeted for 2027. The study will assess tumor response, biomarker-driven immune activation, and event-free survival outcomes, representing a key step in establishing clinical validation for Gedeptin in combination immuno-oncology strategies.
In parallel, GeoVax is expanding preclinical work across additional solid tumor indications to identify settings where combination approaches may offer the greatest clinical benefit. These efforts aim to support expansion beyond head and neck cancer and inform future clinical development strategies.
The company is actively pursuing opportunities to advance Gedeptin through clinical development partnerships, combination-focused collaborations, and potential licensing or co-development arrangements. “We are entering an important phase of development for Gedeptin, with a focus on clinical execution and advancing discussions around potential partnerships,” said David A. Dodd, Chairman and CEO of GeoVax. “As combination therapy becomes more common across oncology, we believe Gedeptin is well positioned to be integrated into these regimens and contribute to improved treatment outcomes.”
GeoVax has established a foundation to support Gedeptin’s advancement, including completed Phase 1/2 clinical experience in advanced head and neck cancer, engagement of an Oncology Advisory Board with deep immuno-oncology expertise, and expanded intellectual property supporting combination use with checkpoint inhibitors. This foundation is intended to support both continued clinical progression and engagement with potential partners.
Gedeptin is a gene-directed enzyme prodrug therapy delivered intratumorally using a non-replicating viral vector encoding purine nucleoside phosphorylase (PNP). After systemic administration of a prodrug, the encoded enzyme converts it into a cytotoxic agent directly within the tumor microenvironment.
GeoVax is also advancing other programs, including GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox, which is expected to enter a pivotal Phase 3 trial in the second half of 2026. The company’s pipeline includes GEO-CM04S1, a next-generation COVID-19 vaccine candidate being evaluated in immunocompromised populations. For more information, visit www.geovax.com.
The convergence of upcoming clinical milestones and increasing industry focus on combination approaches creates a timely opportunity for Gedeptin, according to GeoVax. As the oncology field moves toward multi-modal treatment regimens, the ability to integrate into established backbones is becoming a critical factor for clinical and commercial success.
